Industry leading producer of neurons and glia paving the way for advancements in neuroscience.
BrainXell was established in 2015 by Dr. Su-Chun Zhang, a pioneer in stem cell neuroscience, in collaboration with the University of Wisconsin–Madison’s Discovery to Product (D2P) program, to translate cutting-edge research into meaningful therapies. Today, the team works with both large and small biotech and pharmaceutical partners to develop products, services, and applications using its proprietary technology to guide human stem cells—including induced pluripotent stem cells (iPSCs)—into highly enriched, specialized neurons. BrainXell is working to bring hope to patients with neurological conditions.
Our company is based on directed differentiation of human stem cells (including iPSCs) to highly enriched subclasses of neurons. BrainXell provides a range of high-purity, iPSC-derived human neurons for research and development with a focus on drug discovery. From motor neurons to cortical sub-types, we can provide specific models for both disease or normal drug screening. We are dedicated to delivering the highest quality products from both our off-the-shelf neurons as well as custom service projects.
BrainXell serves neuroscientists around the world. We provide products in North America and many other countries directly:
Abcam – BioClone – Bio-Connect B.V. – BIOZOL Diagnostica Vertrieb GmbH – CliniSciences
Funakoshi Co., Ltd. – OMNICELL Pte Ltd – Quimigen
BrainXell’s mission is to drive innovation for the most relevant human CNS disease and normal cell models.